New antibody therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07192614

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people to see if it shrinks tumors or lowers PSA levels. About 52 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Orlando, Florida, 32806, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
WITHDRAWN

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

Grand Rapids, Michigan, 49546, United States
Research Site
RECRUITING

Commack, New York, 11725, United States
Research Site
RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
NOT_YET_RECRUITING

Brussels, 1200, Belgium
Research Site
NOT_YET_RECRUITING

Ghent, 9000, Belgium
Research Site
NOT_YET_RECRUITING

Toronto, Ontario, M4N 3M5, Canada
Research Site
RECRUITING

Québec, G1J 1Z4, Canada
Research Site
RECRUITING

Beijing, 100142, China
Research Site
SUSPENDED

Chengdu, 610041, China
Research Site
SUSPENDED

Guangzhou, 510060, China
Research Site
NOT_YET_RECRUITING

Nanjing, 2100008, China
Research Site
RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Hirakata-shi, 573-1191, Japan
Research Site
NOT_YET_RECRUITING

Kashiwa, 277-8577, Japan
Research Site
NOT_YET_RECRUITING

Amsterdam, 1066CX, Netherlands
Research Site
NOT_YET_RECRUITING

Maastricht, 6229 HX, Netherlands
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 5505, South Korea
Research Site
NOT_YET_RECRUITING

Barcelona, 8035, Spain
Research Site
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, 08908, Spain
Research Site
NOT_YET_RECRUITING

Madrid, 28041, Spain
Research Site
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Research Site
NOT_YET_RECRUITING

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.